Well, if they can offload 100,000 courses of Ropren before the end of this financial year at $2000 each, we're looking at $200 million revenue, and if 50% makes it to the bottom line, 50c per share profit. On a PE of 20 that's $10 a share, and they could easily pay a 20c dividend and still have 60 million cash for the year to upgrade factories, R&D etc.